Dirk Schmidt-Arras

Dirk Schmidt-Arras serves as an Associate Professor in the Faculty of Life Sciences and Medical Biology at the University of Salzburg, Austria. His research program focuses on molecular signaling pathways in cancer development and progression, with particular emphasis on metalloproteases and cytokine signaling networks. He maintains an active research laboratory with multiple ongoing projects funded through 2029, including significant contributions to the Cancer Cluster Salzburg III initiative.

Dr. Schmidt-Arras's research interests span several interconnected domains in molecular oncology. His primary focus involves the ADAM family of metalloproteases, particularly ADAM17, and their critical roles in cancer progression through regulation of cytokine signaling. His work extensively investigates IL-6/gp130 signaling pathways in liver and breast cancer contexts, examining how these pathways influence tumor microenvironment, DNA damage response, and metastasis. His laboratory also explores therapeutic targeting of these pathways, with recent work on NLRP3 inhibition in leukemia and spatial cross-talk in immuno-oncology.

The publication record of Dr. Schmidt-Arras reveals a strong thematic continuity in cancer signaling research spanning two decades, with increasing focus on translational applications in recent years. His most recent work demonstrates sophisticated integration of multiple signaling pathways (IL-6, EGFR, gp130) in cancer contexts, with particular attention to tumor microenvironment and therapeutic targeting. The research demonstrates methodological diversity across cell biology, molecular signaling, and in vivo models, with growing emphasis on clinical translation as evidenced by multiple therapeutic targeting studies in the past five years.

Dr. Schmidt-Arras has secured significant research funding, including leadership roles in multiple multi-year projects: the SAA axis project investigating IL-6 signaling in hepatic tumors (2024-2028), the spaXio project on spatial cross-talk in immuno-oncology (2025-2029), and the Micro-environmental ADAM17 project focused on breast cancer (2025-2029). He also serves as a key staff member in the Cancer Cluster Salzburg III initiative, which has received millions in funding as highlighted in press coverage from April 2025.

His research activities extend to active participation in the scientific community through numerous guest lectures on paracrine signaling mechanisms, contributions to major conferences like the ÖGMBT Annual Meeting, and service on appointment committees including chairing the committee for Biochemistry and Metabolism professorship. His laboratory appears to be part of a larger collaborative network focused on cancer research at the University of Salzburg, with particular emphasis on molecular mechanisms of tumor development and potential therapeutic interventions.